Novartis


BeiGene’s Tislelizumab Gets Approval for First-Line Treatment of Advanced Non-Squamous NSCLC in China

China-based biopharmaceutical firm BeiGene (BGNE) has received approval for its anti-PD-1 antibody tislelizumab from the China National Medical Products Administration (NMPA) for the …

Novartis Snaps Up Vedero Bio In $280M Deal; Street Says Buy

Swiss drugmaker Novartis announced the acquisition of ocular gene therapy company Vedere Bio for a total consideration of $280 million. Under the terms …

Novartis’ Skin Cancer Drug Candidate Fails Late-Stage Trial Target

Novartis AG announced on Saturday that its investigational spartalizumab immunotherapy drug combined with Tafinlar and Mekinist therapies failed to meet its primary endpoint …

Novartis To Sell Covid-19 Drugs At Zero-Profit To Low-Income Countries

Novartis AG (NVS) announced Thursday that its Sandoz division will sell 15 generic drugs to treat COVID-19 symptoms at zero-profit to governments in …

Novartis Gets FDA Nod to Start Malaria Drug Trial For Coronavirus Cure

Swiss drugmaker Novartis AG (NVS) announced on Monday that it reached an agreement with U.S.

Novartis Buys U.S. Start-Up Amblyotech For Lazy Eye Treatment

Swiss drugmaker Novartis AG (NVS) said Monday it has acquired U.S.

Incyte, Novartis Initiate Phase 3 Jakavi Drug Study For Coronavirus Treatment  

Global biotech company Incyte (INCY) announced on Friday that it has initiated a Phase 3 clinical trial in collaboration with Novartis (NVS) to …

Here’s Why AveXis (AVXS) Investors Are Celebrating Today

AveXis (NASDAQ:AVXS) investors are busy throwing a party today following the news that Novartis (NYSE:NVS) has reached an agreement to acquire AveXis for …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts